$LFST

Bessler Robert sold $9.1M of LFST (indirect holdings)

Bessler Robert sold 894,337 indirectly-held shares of LifeStance Health Group, Inc. (LFST) at $10.13 ($9.06M total) across 2 trades on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bessler Robert
Published Jun 30, 2026, 8:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LFST
Neutral
medium confidence
Mentioned
$LFST
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

Provides a concrete, newly filed datapoint on insider selling size, price, and post-transaction holdings, which can affect short-term sentiment but not fundamentals by itself.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing generally limits the signal strength.

03

What to watch

The disclosure is indirect holdings and pre-arranged; without additional context (e.g., total insider activity, other filings), directional inference is weak.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-30; transaction dated 2026-06-26 (after-hours/next-session read-through).

Background

The article is an SEC Form 4 insider transaction: director Robert Bessler sold LifeStance Health Group shares via an open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$LFSTNeutralMedium confidence
Context

LifeStance Health Group director Robert Bessler sold 894,337 shares in an open-market transaction under a 10b5-1 plan at $10.13.

Expected impact

Likely limited immediate impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size and price, but it explicitly states a pre-arranged 10b5-1 plan, reducing interpretive weight.

Market effects

No sector-level read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, large sales can coincide with personal liquidity needs or risk management, which some traders may still interpret as caution.

Key entities

  • LifeStance Health Group, Inc.

    Subject of the Form 4 insider transaction; director Robert Bessler sold shares under a 10b5-1 plan.

  • Robert Bessler

    Director who executed the open-market sale; transaction disclosed on SEC EDGAR.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LFSTMedAI 8/10

LifeStance Health Group, Inc. Q2 2026 Earnings Call Summary

LifeStance Health Group reported Q2 2026 revenue growth of 26%, driven by higher visit volumes and a 6% rise in revenue per visit, and said visits per clinician rose 7% YoY. The company raised full-year 2026 guidance to $1.685B-$1.725B revenue and 13.2% adjusted EBITDA margins, approved a new $100M buyback, and reported Q2 free cash flow of $88M.